GENE ONLINE|News &
Opinion
Blog

2025-12-01|

Study Explores Role of Arabinoxylan in Modulating Gut-Brain Pathways Linked to Post-Stroke Depression

by GOAI
Share To

A recent study has explored the potential role of arabinoxylan, a plant-derived hemicellulose, in influencing brain signaling pathways associated with post-stroke depression. Researchers examined how this dietary fiber interacts with gut microbiota and its subsequent effects on mood regulation and cognitive function. The findings provide new insights into the neurobiological mechanisms underlying post-stroke depression, highlighting a possible link between diet and mental health.

The research focused on arabinoxylan’s ability to modulate brain signaling through its interaction with gut bacteria. This compound, commonly found in plant cell walls, appears to influence key pathways involved in mood and cognition. The study delved into how changes in gut microbiota composition may impact neurological processes following a stroke. While the specific details of the mechanisms remain under investigation, the results suggest that dietary interventions involving arabinoxylan could play a role in addressing post-stroke depression symptoms. Further studies are expected to expand on these initial findings to better understand their implications for treatment strategies.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 1, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top